Volume | 726,059 |
|
|||||
News | - | ||||||
Day High | 36.5054 | Low High |
|||||
Day Low | 34.9226 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Collegium Pharmaceutical Inc | COLL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
35.00 | 34.9226 | 36.5054 | 35.94 | 34.74 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
7,057 | 726,059 | $ 35.90 | $ 26,066,557 | - | 20.83 - 40.95 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:50 | 1 | $ 36.68 | USD |
Collegium Pharmaceutical Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.15B | 31.96M | - | 566.77M | 48.16M | 1.51 | 23.85 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Collegium Pharmaceutical News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical COLL Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 35.03 | 36.5054 | 34.24 | 35.02 | 301,772 | 0.91 | 2.60% |
1 Month | 40.32 | 40.95 | 34.24 | 37.64 | 341,016 | -4.38 | -10.86% |
3 Months | 33.87 | 40.95 | 31.34 | 36.71 | 418,852 | 2.07 | 6.11% |
6 Months | 21.28 | 40.95 | 20.95 | 32.33 | 414,278 | 14.66 | 68.89% |
1 Year | 22.98 | 40.95 | 20.83 | 28.26 | 361,813 | 12.96 | 56.40% |
3 Years | 23.59 | 40.95 | 14.04 | 23.61 | 333,075 | 12.35 | 52.35% |
5 Years | 14.18 | 40.95 | 10.01 | 21.57 | 368,175 | 21.76 | 153.46% |
Collegium Pharmaceutical Description
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol. |